Zoetis Inc. shares dropped to a 52-week low of $71.41 on Tuesday, marking the lowest valuation for the pharmaceutical company since July 2023.
The decline comes amid broader weakness in the healthcare sector, which has faced headwinds from rising regulatory scrutiny and margin pressures. Zoetis, a leading animal health company, has also been impacted by softer demand in key markets, including North America and Europe.
The stock’s recent performance contrasts with its 52-week high of $89.90, reached in March 2024, reflecting a decline of roughly 20% from that peak. Analysts attribute the downturn to a combination of macroeconomic factors, including higher interest rates and reduced discretionary spending by pet owners.
Zoetis has not provided an official comment on the stock’s decline. The company’s next earnings report is scheduled for late October, which may offer further clarity on its financial trajectory.
